Vigilare Wealth Management Cuts Stake in AbbVie Inc. (NYSE:ABBV)

Vigilare Wealth Management cut its stake in AbbVie Inc. (NYSE:ABBVFree Report) by 18.0% during the 2nd quarter, HoldingsChannel reports. The firm owned 2,828 shares of the company’s stock after selling 619 shares during the quarter. Vigilare Wealth Management’s holdings in AbbVie were worth $381,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in ABBV. Johnson & White Wealth Management LLC acquired a new stake in shares of AbbVie during the first quarter valued at about $721,000. Sand Hill Global Advisors LLC grew its stake in shares of AbbVie by 0.4% during the first quarter. Sand Hill Global Advisors LLC now owns 18,755 shares of the company’s stock valued at $2,989,000 after acquiring an additional 68 shares in the last quarter. Chesapeake Wealth Management grew its stake in shares of AbbVie by 21.4% during the fourth quarter. Chesapeake Wealth Management now owns 13,083 shares of the company’s stock valued at $2,114,000 after acquiring an additional 2,305 shares in the last quarter. Quintet Private Bank Europe S.A. acquired a new stake in shares of AbbVie during the first quarter valued at about $6,686,000. Finally, Capital Market Strategies LLC grew its stake in shares of AbbVie by 5.0% during the first quarter. Capital Market Strategies LLC now owns 12,027 shares of the company’s stock valued at $1,917,000 after acquiring an additional 575 shares in the last quarter. 67.86% of the stock is owned by hedge funds and other institutional investors.

AbbVie Stock Performance

ABBV opened at $153.93 on Tuesday. The business’s 50 day moving average is $146.42 and its 200-day moving average is $147.44. The stock has a market cap of $271.69 billion, a PE ratio of 31.67, a price-to-earnings-growth ratio of 2.79 and a beta of 0.58. The company has a current ratio of 0.89, a quick ratio of 0.77 and a debt-to-equity ratio of 4.33. AbbVie Inc. has a twelve month low of $130.96 and a twelve month high of $168.11.

AbbVie (NYSE:ABBVGet Free Report) last released its quarterly earnings results on Thursday, July 27th. The company reported $2.91 earnings per share for the quarter, beating analysts’ consensus estimates of $2.79 by $0.12. The company had revenue of $13.87 billion for the quarter, compared to analysts’ expectations of $13.52 billion. AbbVie had a return on equity of 151.29% and a net margin of 15.50%. On average, analysts predict that AbbVie Inc. will post 11.03 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 15th. Stockholders of record on Friday, October 13th will be issued a dividend of $1.48 per share. The ex-dividend date is Thursday, October 12th. This represents a $5.92 dividend on an annualized basis and a dividend yield of 3.85%. AbbVie’s dividend payout ratio (DPR) is presently 121.81%.

Analyst Ratings Changes

ABBV has been the subject of a number of research reports. StockNews.com initiated coverage on AbbVie in a research note on Thursday, August 17th. They issued a “strong-buy” rating for the company. Credit Suisse Group decreased their price target on AbbVie from $170.00 to $160.00 in a research note on Wednesday, July 12th. William Blair initiated coverage on AbbVie in a research note on Tuesday, July 25th. They issued a “market perform” rating for the company. HSBC initiated coverage on AbbVie in a research note on Friday, July 14th. They issued a “buy” rating and a $167.00 price target for the company. Finally, Piper Sandler lifted their price target on AbbVie from $163.00 to $170.00 and gave the stock an “overweight” rating in a research note on Friday, July 28th. Eight analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $165.79.

View Our Latest Stock Analysis on ABBV

Insider Activity

In related news, CEO Richard A. Gonzalez sold 18,500 shares of the business’s stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $149.15, for a total transaction of $2,759,275.00. Following the sale, the chief executive officer now owns 625,294 shares of the company’s stock, valued at $93,262,600.10. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.26% of the company’s stock.

AbbVie Company Profile

(Free Report)

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Beh├žet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies.

See Also

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBVFree Report).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.